Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

Aeolus Pharmaceuticals, Inc. (AOLS)

Aeolus Pharmaceuticals is a biotechnology company developing compounds to protect against radiological and chemical threats. The company is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Their first compound is AEOL 10150.

The company’s AEOL 10150 is undergoing development, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons. Its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure.

Aeolus Pharmaceuticals’ strategy is to take advantage of the considerable investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology.

AEOL 10150 is a broad-spectrum catalytic antioxidant. It is specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.

AEOL 10150 has performed well in animal safety studies. It was well-tolerated in two human clinical trials. In addition, it has demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Moreover, AEOL 10150 is presently in development for use as a therapeutic and prophylactic drug in cancer patients.

Recently, Aeolus Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority (BARDA) exercised $6.0 million in additional contract options under their advanced research and development contract for AEOL-10150. Aeolus is developing their lead compound, AEOL-10150, as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a five year contract with BARDA worth up to $118MM. The contract was awarded on February 11, 2011. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats.

AEOL 10150 is additionally being studied by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract and by NIH CounterACT as a countermeasure against chlorine gas and sulfur mustard gas exposure.

The company has selected AEOL 11207 as their second development candidate. Data collected to date suggest that AEOL 11207 may be useful as a potential once-every-other-day oral therapeutic treatment option for central nervous system (CNS) disorders, most probably Parkinson’s disease.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue